Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision

Li, Xiaoyang; Pomarès, Christelle; Peyron, François; Press, Cynthia; Ramirez, Raymund; Gonfrier, Géraldine; Cannavo, Isabelle; Chapey, Emmanuelle; Levigne, Pauline; Wallon, Martine; Montoya, José G.; Dai, Hongjie

doi:10.1007/s10096-019-03487-1

Cited by 27 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the rapid advances of nanotechnology, a nanostructured plasmonic gold (pGOLD) substrate 29,[31][32][33][34] has been developed for highly sensitive serology antibody assays. The pGOLD substrate is composed of nanoscale gold islands with abundant nanogaps, affording near-infrared (NIR) fluorescence enhancement by up to ~100-fold due to plasmonic resonance and local electric field enhancements 29,[31][32][33][34] . The increased NIR signal-to-background ratio on pGOLD allows multiplexed detection of panels of biological analytes over wide dynamic ranges.…”

mentioning

confidence: 99%

“…The increased NIR signal-to-background ratio on pGOLD allows multiplexed detection of panels of biological analytes over wide dynamic ranges. Previous antigen arrays on pGOLD have simultaneously detected IgG, IgM and IgA antibody subtypes for type 1 diabetes 32 , toxoplasmosis 34 , hepatitis delta virus (HDV) 35 , and Zika and Dengue viral infections 29 . In particular, the pGOLD toxoplasmosis 34 and HDV 35 IgG antibody assays reached ~100% sensitivity because of the exquisite NIR detection capabilities on the nanotechnology substrate.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Liu¹,

Hsiung²,

Zhao³

et al. 2020

Nat Biomed Eng

Self Cite

View full text Add to dashboard Cite

Accurate assays for the detection of antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are essential for the control of the COVID-19 (coronavirus disease 2019) pandemic. Here, we report antibody and antibody-avidity assays, relying on near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to the receptor binding domain of SARS-CoV-2 in human serum and saliva, and for quantifying immunoglobulin avidities against coronavirus antigens from SARS-CoV-2, SARS-CoV-1 and the common-cold viruses OC43, HKU1, NL63 and 229E. The antibody assay detected immunoglobulin M in 87% (52 of 60) COVID-19-positive serum samples collected 6 or more days after symptom onset (and the immunoglobulins M and G in all 33 samples collected at least 15 days after symptom onset), and correctly classified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected before the pandemic, including 73 that were positive for other viruses). We used the antibody-avidity assay to study antibody-maturation patterns, anamnestic responses, and cross-immunity to the common-cold coronaviruses.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Liu¹,

Hsiung²,

Zhao³

et al. 2020

Nat Biomed Eng

Self Cite

View full text Add to dashboard Cite

show abstract

“…Here we developed a high accuracy, semi-quantitative assay on the nanostructured plasmonic gold (pGOLD) platform [4][5][6][7][8] for detecting IgG, IgM and IgG avidity against SARS-CoV-2 spike proteins S1 subunit and RBD 1, 3,35 in human serum and saliva. The pGOLD substrate was comprised of nanoscale gold islands with abundant nanogaps, affording nearinfrared (NIR) fluorescence enhancement by up to ~ 100-fold owing to plasmonic resonance and local electric field enhancements [4][5][6][7][8] . The greatly increased NIR signal-to-background ratio on pGOLD allowed multiplexed detection of panels of biological analytes over wide dynamic ranges.…”

mentioning

confidence: 99%

“…Previous antigen arrays on pGOLD simultaneously detected IgG, IgM, and IgA antibody subtypes for type 1 diabetes 5 , toxoplasmosis 8 , HDV 36 , Zika, and Dengue viral infections 7 . In particular, the pGOLD toxoplasmosis 8 and HDV 36 IgG antibody assays reached ~ 100 % sensitivity owing to exquisite NIR detection capabilities on the novel nanotechnology platform.…”

mentioning

confidence: 99%

“…Lastly, we exploited the high analytical sensitivity of the nano-plasmonic gold platform for detecting antibodies in human saliva against SARS-CoV-2. It is well known that antibody concentration in human saliva is orders of magnitude lower than in blood or serum, demanding assay platforms with exquisite analytical sensitivity and capable of detecting ultra-high signal over background noise 8 . We tested the saliva samples of 4 fully recovered, PCR-positive COVID-19 patients and 11 healthy non-infected individuals on pGOLD (Fig.5a).…”

mentioning

confidence: 99%

See 1 more Smart Citation

High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

Liu¹,

Hsiung²,

Zhao³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

The outbreak and rapid spread of SARS-CoV-2 virus has led to a dire global pandemic with millions of people infected and ~ 400,000 deaths thus far. Highly accurate detection of antibodies for COVID-19 is an indispensable part of the effort to combat the pandemic 1,2 . Here we developed two-plex antibody detection against SARS-CoV-2 spike proteins 3 (the S1 subunit and receptor binding domain RBD) in human serum and saliva on a near-infrared nanoplasmonic gold (pGOLD) platform 4-8 . By testing nearly 600 serum samples, pGOLD COVID-19 assay achieved ~ 99.78 % specificity for detecting both IgG and IgM with 100 % sensitivity in sera collected > 14 days post disease symptom onset, with zero cross-reactivity to other diseases. Two-plex correlation analysis revealed higher binding of serum IgM to RBD than to S1. IgG antibody avidity toward multiple antigens were measured, shedding light on antibody maturation in COVID-19 patients and affording a powerful tool for differentiating recent from remote infections and identifying re-infection by SARS-CoV-2. Just as important, due to high analytical sensitivity, the pGOLD COVID-19 assay detected minute amounts of antibodies in human saliva, offering the first non-invasive detection of SARS-CoV-2 antibodies.

show abstract

Plasmonic Fluorescence Enhancement in Diagnostics for Clinical Tests at Point‐of‐Care: A Review of Recent Technologies

et al. 2022

View full text Add to dashboard Cite

Fluorescence‐based biosensors have widely been used in the life‐sciences and biomedical applications due to their low limit of detection and a diverse selection of fluorophores that enable simultaneous measurements of multiple biomarkers. Recent research effort has been made to implement fluorescent biosensors into the exploding field of point‐of‐care testing (POCT), which uses cost‐effective strategies for rapid and affordable diagnostic testing. However, fluorescence‐based assays often suffer from their feeble signal at low analyte concentrations, which often requires sophisticated, costly, and bulky instrumentation to maintain high detection sensitivity. Metal‐ and metal oxide‐based nanostructures offer a simple solution to increase the output signal from fluorescent biosensors due to the generation of high field enhancements close to a metal or metal oxide surface, which has been shown to improve the excitation rate, quantum yield, photostability, and radiation pattern of fluorophores. This article provides an overview of existing biosensors that employ various strategies for fluorescence enhancement via nanostructures and have demonstrated the potential for use as POCT. Biosensors using nanostructures such as planar substrates, freestanding nanoparticles, and metal–dielectric–metal nanocavities are discussed with an emphasis placed on technologies that have shown promise towards POCT applications without the need for centralized laboratories.

show abstract

Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision

Cited by 27 publications

References 27 publications

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

Plasmonic Fluorescence Enhancement in Diagnostics for Clinical Tests at Point‐of‐Care: A Review of Recent Technologies

Contact Info

Product

Resources

About